Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787363 | 0.89 | TSHR (0.61) | MEN1KMT2ATSHRMAPTENPP1 | |
| SCHEMBL1790852 | 0.84 | ADRA1A (0.60) | TSHRSMN1; SMN2 | |
| SCHEMBL13721057 | 0.76 | ADRA1A (0.44) | TSHRENPP1 | |
| SCHEMBL27585122 | 0.74 | MEN1 (0.54) | MEN1KMT2ATSHRPOLBTP53 | |
| SCHEMBL7892606 | 0.71 | MEN1 (0.74) | MEN1KMT2ATSHRPOLBTP53 | |
| SCHEMBL8556390 | 0.70 | ENPP1 (0.65) | TSHRPOLBSMN1; SMN2MAPTENPP1 | |
| SCHEMBL13720706 | 0.70 | DDAH1 (0.38) | MEN1KMT2AMAPT | |
| SCHEMBL905630 | 0.69 | AR (0.79) | TSHRENPP1 | |
| SCHEMBL24000713 | 0.69 | ENPP1 (0.67) | TSHRPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL13858652 | 0.69 | TSHR (0.44) | MEN1KMT2ATSHRPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2012158399-A1 | CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | MEN1 1274/4885KMT2A 574/4885TSHR 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.